Cargando…
Ex vivo comparison of V.A.C.® Granufoam Silver™ and V.A.C.® Granufoam™ loaded with a first-in-class bis-dialkylnorspermidine-terphenyl antibiofilm agent
Implementation of negative pressure wound therapy (NPWT) as a standard of care has proven efficacious in reducing both the healing time and likelihood of nosocomial infection among pressure ulcers and traumatic, combat-related injuries. However, current formulations may not target or dramatically re...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359492/ https://www.ncbi.nlm.nih.gov/pubmed/37484784 http://dx.doi.org/10.1016/j.bioflm.2023.100142 |
_version_ | 1785075894807691264 |
---|---|
author | Rawson, Kaden B. Neuberger, Travis Smith, Tyler B. Bell, Isaac J. Looper, Ryan E. Sebahar, Paul R. Haussener, Travis J. Kanna Reddy, Hariprasada Reddy Isaacson, Brad M. Shero, John Pasquina, Paul F. Williams, Dustin L. |
author_facet | Rawson, Kaden B. Neuberger, Travis Smith, Tyler B. Bell, Isaac J. Looper, Ryan E. Sebahar, Paul R. Haussener, Travis J. Kanna Reddy, Hariprasada Reddy Isaacson, Brad M. Shero, John Pasquina, Paul F. Williams, Dustin L. |
author_sort | Rawson, Kaden B. |
collection | PubMed |
description | Implementation of negative pressure wound therapy (NPWT) as a standard of care has proven efficacious in reducing both the healing time and likelihood of nosocomial infection among pressure ulcers and traumatic, combat-related injuries. However, current formulations may not target or dramatically reduce bacterial biofilm burden following therapy. The purpose of this study was to determine the antibiofilm efficacy of an open-cell polyurethane (PU) foam (V.A.C.® Granufoam™) loaded with a first-in-class compound (CZ-01179) as the active release agent integrated via lyophilized hydrogel scaffolding. An ex vivo porcine excision wound model was designed to perform antibiofilm efficacy testing in the presence of NPWT. PU foam samples loaded with a 10.0% w/w formulation of CZ-01179 and 0.5% hyaluronic acid were prepared and tested against current standards of care: V.A.C.® Granufoam Silver™ and V.A.C.® Granufoam™. We observed statistically significant reduction of methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii biofilms with the CZ-01179 antibiofilm foam in comparison to current standard of care foams. These findings motivate further development of an antibiofilm PU foam loaded with CZ-01179. |
format | Online Article Text |
id | pubmed-10359492 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-103594922023-07-22 Ex vivo comparison of V.A.C.® Granufoam Silver™ and V.A.C.® Granufoam™ loaded with a first-in-class bis-dialkylnorspermidine-terphenyl antibiofilm agent Rawson, Kaden B. Neuberger, Travis Smith, Tyler B. Bell, Isaac J. Looper, Ryan E. Sebahar, Paul R. Haussener, Travis J. Kanna Reddy, Hariprasada Reddy Isaacson, Brad M. Shero, John Pasquina, Paul F. Williams, Dustin L. Biofilm Article Implementation of negative pressure wound therapy (NPWT) as a standard of care has proven efficacious in reducing both the healing time and likelihood of nosocomial infection among pressure ulcers and traumatic, combat-related injuries. However, current formulations may not target or dramatically reduce bacterial biofilm burden following therapy. The purpose of this study was to determine the antibiofilm efficacy of an open-cell polyurethane (PU) foam (V.A.C.® Granufoam™) loaded with a first-in-class compound (CZ-01179) as the active release agent integrated via lyophilized hydrogel scaffolding. An ex vivo porcine excision wound model was designed to perform antibiofilm efficacy testing in the presence of NPWT. PU foam samples loaded with a 10.0% w/w formulation of CZ-01179 and 0.5% hyaluronic acid were prepared and tested against current standards of care: V.A.C.® Granufoam Silver™ and V.A.C.® Granufoam™. We observed statistically significant reduction of methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii biofilms with the CZ-01179 antibiofilm foam in comparison to current standard of care foams. These findings motivate further development of an antibiofilm PU foam loaded with CZ-01179. Elsevier 2023-07-11 /pmc/articles/PMC10359492/ /pubmed/37484784 http://dx.doi.org/10.1016/j.bioflm.2023.100142 Text en © 2023 The Authors. Published by Elsevier B.V. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rawson, Kaden B. Neuberger, Travis Smith, Tyler B. Bell, Isaac J. Looper, Ryan E. Sebahar, Paul R. Haussener, Travis J. Kanna Reddy, Hariprasada Reddy Isaacson, Brad M. Shero, John Pasquina, Paul F. Williams, Dustin L. Ex vivo comparison of V.A.C.® Granufoam Silver™ and V.A.C.® Granufoam™ loaded with a first-in-class bis-dialkylnorspermidine-terphenyl antibiofilm agent |
title | Ex vivo comparison of V.A.C.® Granufoam Silver™ and V.A.C.® Granufoam™ loaded with a first-in-class bis-dialkylnorspermidine-terphenyl antibiofilm agent |
title_full | Ex vivo comparison of V.A.C.® Granufoam Silver™ and V.A.C.® Granufoam™ loaded with a first-in-class bis-dialkylnorspermidine-terphenyl antibiofilm agent |
title_fullStr | Ex vivo comparison of V.A.C.® Granufoam Silver™ and V.A.C.® Granufoam™ loaded with a first-in-class bis-dialkylnorspermidine-terphenyl antibiofilm agent |
title_full_unstemmed | Ex vivo comparison of V.A.C.® Granufoam Silver™ and V.A.C.® Granufoam™ loaded with a first-in-class bis-dialkylnorspermidine-terphenyl antibiofilm agent |
title_short | Ex vivo comparison of V.A.C.® Granufoam Silver™ and V.A.C.® Granufoam™ loaded with a first-in-class bis-dialkylnorspermidine-terphenyl antibiofilm agent |
title_sort | ex vivo comparison of v.a.c.® granufoam silver™ and v.a.c.® granufoam™ loaded with a first-in-class bis-dialkylnorspermidine-terphenyl antibiofilm agent |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359492/ https://www.ncbi.nlm.nih.gov/pubmed/37484784 http://dx.doi.org/10.1016/j.bioflm.2023.100142 |
work_keys_str_mv | AT rawsonkadenb exvivocomparisonofvacgranufoamsilverandvacgranufoamloadedwithafirstinclassbisdialkylnorspermidineterphenylantibiofilmagent AT neubergertravis exvivocomparisonofvacgranufoamsilverandvacgranufoamloadedwithafirstinclassbisdialkylnorspermidineterphenylantibiofilmagent AT smithtylerb exvivocomparisonofvacgranufoamsilverandvacgranufoamloadedwithafirstinclassbisdialkylnorspermidineterphenylantibiofilmagent AT bellisaacj exvivocomparisonofvacgranufoamsilverandvacgranufoamloadedwithafirstinclassbisdialkylnorspermidineterphenylantibiofilmagent AT looperryane exvivocomparisonofvacgranufoamsilverandvacgranufoamloadedwithafirstinclassbisdialkylnorspermidineterphenylantibiofilmagent AT sebaharpaulr exvivocomparisonofvacgranufoamsilverandvacgranufoamloadedwithafirstinclassbisdialkylnorspermidineterphenylantibiofilmagent AT haussenertravisj exvivocomparisonofvacgranufoamsilverandvacgranufoamloadedwithafirstinclassbisdialkylnorspermidineterphenylantibiofilmagent AT kannareddyhariprasadareddy exvivocomparisonofvacgranufoamsilverandvacgranufoamloadedwithafirstinclassbisdialkylnorspermidineterphenylantibiofilmagent AT isaacsonbradm exvivocomparisonofvacgranufoamsilverandvacgranufoamloadedwithafirstinclassbisdialkylnorspermidineterphenylantibiofilmagent AT sherojohn exvivocomparisonofvacgranufoamsilverandvacgranufoamloadedwithafirstinclassbisdialkylnorspermidineterphenylantibiofilmagent AT pasquinapaulf exvivocomparisonofvacgranufoamsilverandvacgranufoamloadedwithafirstinclassbisdialkylnorspermidineterphenylantibiofilmagent AT williamsdustinl exvivocomparisonofvacgranufoamsilverandvacgranufoamloadedwithafirstinclassbisdialkylnorspermidineterphenylantibiofilmagent |